Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery

[1] Goldstraw P(2007)The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 706-714

[2] Crowley J(1997)Revisions in the International System for Staging Lung Cancer Chest 111 1710-1717

[3] Chansky K(2005)Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study Lung Cancer 50 227-234

[4] Giroux DJ(2012)A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903) Cancer 118 6126-6135

[5] Groome PA(2012)Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer World J Surg 36 1199-1205

[6] Rami-Porta R(2003)Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial J Clin Oncol 21 1752-1759

[7] Postmus PE(2006)Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study Br J Cancer 94 1099-1106

[8] Rusch V(2008)ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy Cancer 113 1379-1386

[9] Sobin L(2006)Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer? Lung Cancer 53 323-330

[10] Mountain CF(2009)The new lung cancer staging system Chest 136 260-271

[1] Goldstraw P(2007)The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 706-714

[2] Crowley J(1997)Revisions in the International System for Staging Lung Cancer Chest 111 1710-1717

[3] Chansky K(2005)Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study Lung Cancer 50 227-234

[4] Giroux DJ(2012)A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903) Cancer 118 6126-6135

[5] Groome PA(2012)Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer World J Surg 36 1199-1205

[6] Rami-Porta R(2003)Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial J Clin Oncol 21 1752-1759

[7] Postmus PE(2006)Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study Br J Cancer 94 1099-1106

[8] Rusch V(2008)ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy Cancer 113 1379-1386

[9] Sobin L(2006)Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer? Lung Cancer 53 323-330

[10] Mountain CF(2009)The new lung cancer staging system Chest 136 260-271